Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MITO 26 phase II trial of trabectedin in advanced uterine and ovarian carcinosarcoma
2015-005153-12Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Dec 2020
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in endometrial carcinosarcoma and ovarian carcinosarcoma (OCS), sponsored by Policlinico Gemelli. Primary endpoint: Objective response rate. Started Dec 2020; status: completed.
02
Drugs
trabectedin
03
Conditions
endometrial carcinosarcomaovarian carcinosarcoma (OCS)
Beyond the preview
Go deeper on 2015-005153-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005153-12.